Ketamine Therapy in Massachusetts

Massachusetts ketamine clinics operate under a well-established regulatory framework governed by both state and federal oversight. At the federal level, ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning that any provider administering or prescribing it must hold a valid DEA registration. At the state level, the Massachusetts Department of Public Health (DPH) and the Board of Registration in Medicine (BORIM) oversee physician licensing and clinical practice standards. Nurse practitioners and other advanced practice providers are regulated by the Board of Registration in Nursing, and all prescribing clinicians must comply with the Massachusetts Prescription Monitoring Program (PMP), which tracks controlled substance prescriptions to prevent misuse and diversion.

Ketamine infusion therapy in Massachusetts is currently administered as an off-label use of a legally approved anesthetic medication. The FDA has approved ketamine solely as an anesthetic agent, while its applications for treatment-resistant depression, chronic pain, PTSD, and other conditions fall outside that original approval. Clinics offering these services are not required to obtain a separate specialty license specifically for ketamine therapy, but they must operate as properly licensed medical facilities. Depending on the setting, this may require compliance with regulations governing outpatient clinics, ambulatory surgical centers, or office-based procedures, including protocols for emergency equipment, patient monitoring, and safe medication storage.

It is important to distinguish between intravenous (IV) ketamine infusions and esketamine (Spravato), the FDA-approved nasal spray form of ketamine. Spravato carries specific FDA requirements, including a Risk Evaluation and Mitigation Strategy (REMS) program, which mandates that it be administered and monitored in a certified healthcare setting. IV ketamine clinics are not subject to the REMS program but are still expected to follow best-practice guidelines published by organizations such as the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) and the American Society of Anesthesiologists. Patients seeking treatment are encouraged to verify that their chosen clinic employs board-certified physicians or appropriately credentialed providers with documented experience in ketamine administration.

Massachusetts does not currently have ketamine-specific legislation that is separate from its broader controlled substance and medical practice laws, meaning the regulatory landscape continues to evolve as the clinical use of ketamine expands. Prospective patients and referring providers should confirm that any clinic they consider maintains current DEA and state licensure, conducts thorough pre-treatment medical and psychiatric evaluations, and adheres to informed consent standards. The following are key regulatory bodies and frameworks relevant to ketamine therapy in Massachusetts:

• U.S. Drug Enforcement Administration (DEA) — Schedule III controlled substance registration
• Massachusetts Department of Public Health (DPH) — Facility and clinical oversight
• Board of Registration in Medicine (BORIM) — Physician licensing and discipline
• Massachusetts Prescription Monitoring Program (PMP) — Controlled substance tracking
• FDA REMS Program — Applicable to Spravato (esketamine) certified treatment centers